Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 22, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival ( OS) in the subset of patients without active liver metastases (non-liver metastases, NLM) in the phase 3 STELLAR-303